Identification and evaluation of drug related problems to first line therapy of antitubercular drugs among the pulmonary tuberculosis patients in a tertiary care hospital- A Randomised controlled study


  • Bandaru Yeswanth Raja Department of Pharmacy Practice, KLE college of Pharmacy, KLE Academy of Higher Education and Research, Belagavi-590010, Karnataka, India
  • Madiwalayya Shivakantayya Ganachari Department of Pharmacy Practice, KLE college of Pharmacy, KLE Academy of Higher Education and Research, Belagavi-590010, Karnataka, India



Drug related problems, Adverse drug reactions, Antitubercular drugs, Tuberculosis


The standard treatment involves the use of first line antitubercular therapy for treating pulmonary tuberculosis (TB) in treating pulmonary tuberculosis (TB). This treatment is associated with many drug-related problems (DRPs) and adverse drug reactions (ADRs). A single blind randomized, controlled study was conducted on 250 patients to identify and evaluate the DRPs and ADRs among the newly diagnosed pulmonary TB patients in a tertiary care hospital. The patients were classified as the usual care group (Control) and pharmaceutical care intervention group (Test). At the end of follow up of the study, the DRPs were assessed by using PCNE classification V9.1. The causality assessment of ADRs was done with Naranjo algorithm, severity assessment was carried with modified Hartwig and Siegel scale and the preventability of ADRs was assessed with modified Schumock and Thornton scale. The statistical percentage analysis was done using with Microsoft Excel 2019. Of 250 participants, 88% had DRPs and developed one or more ADRs. The DRPs of Adverse drug event (possibly) occurring, unclear problem/complaint, duration of treatment too long, medication reconciliation problem and inappropriate timing or dosing intervals were found to be more. The severity of ADRs around 94.55% were mild and 5.45% were moderate. The causality of ADRs around 94.09% were possible and 5.92% were probable, while the preventability of ADRs found around 89.55% definitely preventable and 10.45% were probably preventable. The study concludes the importance of clinical pharmacists in pharmaceutical patient care will contribute in understanding different DRPs and ADRs in the management of TB.


Download data is not yet available.


World Health Organization (WHO): Global tuberculosis control, WHO report 2021. 2021. Available from: [].

National Tuberculosis Elimination Programme Annual Status Report. TB India 2016. New Delhi, India: Central TB Division, Ministry of Health and Family Welfare. Available from: [].

Forget EJ, Menzies D. Adverse reactions to first-line antituberculosis drugs. Expert Opin Drug Saf. 2006; 5:231-49.

Al-Quteimat OM, Amer AM. Evidence-based pharmaceutical care: The next chapter in pharmacy practice. Saudi Pharm J. 2016; 24:447-51.

Francis J, Abraham S. Clinical pharmacists: Bridging the gap between patients and physicians. Saudi Pharm J. 2014; 22:600-2.

Marra F, Marra CA, Bruchet N, Richardson K, Moadebi S, Elwood RK, et al. Adverse drug reactions associated with first line anti tuberculosis drug regimens. Int J Tuberc Lung Dis 2007; 11:868 75.

Gillespie U, Al assaad A, Henrohn D, et al. A comprehensive pharmacist intervention to reduce morbidity in patients 80 years or older: a randomized controlled trial. Arch Intern Med. 2009; 169:894–900.

Schnipper JL, Kirwin JL, Cotugno MC, et al. Role of pharmacist counseling in preventing adverse drug events after hospitalization. Arch Intern Med. 2006; 166:565–571.

Classification for Drug related problems [ebook] Pharmaceutical Care Network Europe Association, pp.1-10. 9th ed [cited Nov 21 2021]. Available from: [].

Naranjo CA, Busto U, Sellers EM, Sandor P, Ruis I, Roberts EA, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther. 1981; 30:239–45.

Hartwig SC, Siegel J, Schneider PJ. Preventability and severity assessment in reporting adverse drug reactions. Am J Hosp Pharm. 1992; 49:2229–32.

Schumock GT, Thornton JP. Focusing on the preventability of adverse drug reactions. Hosp Pharm.1992; 27:538.

Conde MB, Lapa E Silva JR. New regimens for reducing the duration of the treatment of drug-susceptible pulmonary tuberculosis. Drug Dev Res. 2011; 72:501-508.

Abu Ruz S, Jaber D, Basheti I, Sadeq A, Arafat M, Al Ahmad M, et al. Impact of pharmacist interventions on drug related problems in general surgery patients: A randomised controlled trial. Eur J Hosp Pharm. 2021; 28:72 8.

Song YK, Jeong S, Han N, Na H, Jang HY, Sohn M, et al. Effectiveness of clinical pharmacist service on drug related problems and patient outcomes for hospitalized patients with chronic kidney disease: A randomized controlled trial. J Clin Med. 2021; 10:1788.

Sagita VA, Bahtiar A, Andrajati R. Evaluation of a clinical pharmacist intervention on clinical and drug related problems among coronary heart disease inpatients: A pre experimental prospective study at a general hospital in Indonesia. Sultan Qaboos Univ Med J. 2018; 18:81 7.

Shivaraj G, Murali krishnan, Nijeesh. Study on drug related problems in tuberculosis patients with co morbidities in a tertiary care teaching hospital. Eur J Pharma Med Rea. 2017; 4:756-67.

Fei C M, Zainal H, Ali I, Ali H. Evaluation of adverse drug reactions induced by anti-tuberculosis drugs in hospital pulau pinang. Malays J Med Sci. 2018; 25:103-14.

Nowinski A, Wesołowski S, Korzeniewska-Koseła M. The impact of comorbidities on tuberculosis treatment outcomes in Poland: a national cohort study. Front Public Health. 2023; 11:1253615.

Gube A A, Debalkie M, Seid K, Kiberlem. Assesment of anti-TB drug nonadherence and associated factors among TB patients attending TB clinics in Arba Minch government health institution. Tuberculosis Res Treatment. 2018:1-7.

Krishna G K, Ananthakrishnan S, Reddy T. Study on adherence to anti tuberculosis drugs under DOTs and Non-DOTs and factors affecting adherence. World J Pharmacy Pharmaceutical Sci. 2020; 6:1973-86.

Tharanon V, Putthipokin K, Sakthong P. Drug-related problems identified during pharmaceutical care interventions in an intensive care unit at a tertiary university hospital. SAGE Open Med. 2022.

Herawati F, Fahmi EY, Pratiwi NA, Ramdani D, Jaelani AK, Yulia R, Andrajati R. Oral anti-tuberculosis drugs: An urgent medication reconciliation at hospitals in Indonesia. J Public Health Res. 2021; 10:1896.

Hema NG, Bhuvana KB, Virupaksha HM. Critical assessment of adverse drug reactions to antitubercular drugs in a government teaching hospital. Int J Basic Med Sci. 2013; 4:60 7.

Ormerod LP, Horsfield N. Frequency and type of reactions to antituberculosis drugs: Observations in routine treatment. Tuber Lung Dis. 1996; 77:37 42.

Schaberg T, Rebhan K, Lode H. Risk factors for side effects of isoniazid, rifampin and pyrazinamide in patients hospitalized for pulmonary tuberculosis. Eur Respir J. 1996; 9:2026 30.






Research Article

How to Cite

“Identification and Evaluation of Drug Related Problems to First Line Therapy of Antitubercular Drugs Among the Pulmonary Tuberculosis Patients in a Tertiary Care Hospital- A Randomised Controlled Study”. International Journal of Pharmaceutical Sciences and Drug Research, vol. 16, no. 2, Mar. 2024, pp. 142-8,